<DOC>
	<DOCNO>NCT00528398</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , idarubicin cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well give idarubicin together high-dose cytarabine work treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Idarubicin High-Dose Cytarabine Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete remission rate ( CR ) . - Determine proportion patient bone marrow-positive day 7 post-induction chemotherapy . - Further evaluate toxicity regimen . OUTLINE : Patients receive cytarabine IV 3 hour every 12 hour day 1-4 idarubicin IV 5-10 minute day 1-3 . Patients undergo bone marrow aspirate biopsy 7 day completion induction chemotherapy . Patients &gt; 25 % cellular biopsy &gt; 10 % abnormal cell aspirate receive 4 dos cytarabine 1 dose idarubicin .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Newly diagnose acute myeloid leukemia ( AML ) Morphologic proof ( bone marrow aspirate smear touch prep marrow biopsy ) disease FAB M0 , M1 , M2 , M4 , M5a , M5b , M6a , M6b , M7 disease Previously untreated radiotherapy chemotherapy Patients treatmentrelated leukemia eligible even receive prior chemotherapy radiotherapy Patients prior myelodysplastic syndrome eligible Extramedullary leukemia allow AML lymphoid marker allow Exclusion criterion : Blastic transformation chronic myelogenous leukemia Biphenotypic leukemia FAB M3 disease ( acute promyelocytic leukemia ) PATIENT CHARACTERISTICS : Life expectancy ≥ 6 week Total bilirubin &lt; 1.5 g/dL AST ALT &lt; 5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 70 mL/min Ejection fraction ≥ 50 % MUGA unless decrease ejection fraction secondary leukemia infiltration HIV antibodynegative PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Prior hydroxyurea corticosteroid allow At least 48 hour since prior concurrent itraconazole fluconazole Exclusion criterion : More 300 mg/m² prior daunorubicin equivalent dose anthracycline</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>